Transgene Biotek Limited (BOM:526139)
2.460
-0.170 (-6.46%)
At close: Jan 20, 2026
Transgene Biotek Company Description
Transgene Biotek Limited, a biotechnology company, provides research and development services for bulk drugs in India.
It offers a portfolio of oncology drugs, oral drug delivery, and biogenerics. The company provides TrabiDHA for use in health food, baby food/formula, health supplement, and chicken and animal feed markets; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption.
The company was incorporated in 1990 and is based in Sangareddy, India.
Transgene Biotek Limited
| Country | India |
| Founded | 1990 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Koteswara Kanuru |
Contact Details
Address: Plot No. 69 & 70 Sangareddy, 502325 India | |
| Phone | 91 40 6558 9499 |
| Website | transgenebiotek.com |
Stock Details
| Ticker Symbol | 526139 |
| Exchange | Bombay Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | INR |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Koteswara Kanuru | Chief Executive Officer |
| Chowdari Prasad | Chief Financial Officer |